NASHVILLE, Tenn. / May 14, 2025 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA)
Format: Fireside Chat, followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025
Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 28, 2025
Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$30.54 |
| Daily Change: | -0.34 -1.10 |
| Daily Volume: | 423,730 |
| Market Cap: | US$1.090B |
March 24, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
